Mealey's (March 15, 2022, 10:16 AM EDT) -- NEW YORK — A federal district court did not err in dismissing shareholder claims in a securities class action lawsuit against drug maker Bristol-Myers Squibb Co. and certain of its current and former senior executives stemming from alleged misstatements the defendants made regarding the design, outcome and risk of a clinical trial for the company’s new non-small cell cancer treatment drug, Opdivo, because the shareholders failed to sufficiently plead that the defendants made any material misstatements or omissions or scienter in pleading their federal securities law claims, a Second Circuit U.S. Court of Appeals panel ruled March 11 in affirming....